Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Shiffman ML, et al. Among authors: di bisceglie am. Gastroenterology. 2007 Jan;132(1):103-12. doi: 10.1053/j.gastro.2006.11.011. Epub 2006 Nov 11. Gastroenterology. 2007. PMID: 17241864 Clinical Trial.
Evolution of hepatitis C viral quasispecies after liver transplantation.
Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, Korber B, Perelson AS, Di Bisceglie AM. Lyra AC, et al. Among authors: di bisceglie am. Gastroenterology. 2002 Nov;123(5):1485-93. doi: 10.1053/gast.2002.36546. Gastroenterology. 2002. PMID: 12404223
Optimal therapy of hepatitis C.
Di Bisceglie AM, Hoofnagle JH. Di Bisceglie AM, et al. Hepatology. 2002 Nov;36(5 Suppl 1):S121-7. doi: 10.1053/jhep.2002.36228. Hepatology. 2002. PMID: 12407585 Review.
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.
Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Di Bisceglie AM, et al. Am J Gastroenterol. 2003 Sep;98(9):2060-3. doi: 10.1111/j.1572-0241.2003.t01-1-07641.x. Am J Gastroenterol. 2003. PMID: 14499788
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Shiffman ML, et al. Among authors: di bisceglie am. Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947. doi: 10.1053/j.gastro.2004.01.014. Gastroenterology. 2004. PMID: 15057741 Clinical Trial.
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Lee WM, et al. Among authors: di bisceglie am. Control Clin Trials. 2004 Oct;25(5):472-92. doi: 10.1016/j.cct.2004.08.003. Control Clin Trials. 2004. PMID: 15465617 Clinical Trial.
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.
Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR; HALT-C Trial Group. Polyak SJ, et al. Among authors: di bisceglie am. Virol J. 2005 Apr 22;2:41. doi: 10.1186/1743-422X-2-41. Virol J. 2005. PMID: 15847697 Free PMC article.
401 results